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Supplemental Methods 
 
Data linkage 
Approximately 75% of English CPRD practices have consented to participate in a linkage scheme, providing 
linked patient-level data from sources including the Office for National Statistics (ONS) for mortality 
information, Hospital Episode Statistics (HES) for hospitalisation data and deprivation data (Index of Multiple 
Deprivation (IMD 2010)).
1
 The IMD is a measure of deprivation at the small area level (Lower Layer Super 
Output Area (LSOA)), which is made up of 7 domain indices related to: income, employment, health, education, 
housing and crime.
2
 Patient-level IMD information is available for the subgroup of English practices that have 
consented to linkage, based on LSOA of residence. 
 
Due to this restriction in participating practices, linkage reduces the sample size and may result in a loss of 
geographical generalisability; however, combining data sources can provide a more enriched and comprehensive 
dataset.
3,4
 Importantly, linking to hospital and death records allows for identification of further cases of MACE.
3
 
Recording of secondary care information into patient primary care records is generally inputted manually from 
hospital discharge letters or referral notes. This can result in under-recording, inaccuracies, and delays in the 
recording of diagnoses made in secondary care. 
3
 A comparison between CPRD and secondary care data on the 
incidence of myocardial infarction identified a 25% lower rate when using CPRD data alone compared to using 
fully-linked data. 
3
 Using a combination of CPRD, HES, and ONS data was particularly important for this study 
to try and reduce the potential of underestimation of cardiovascular events and identification of cardiovascular 
deaths. 
 
Definition of baseline biological variables 
To increase data availability for defining obesity and chronic kidney disease, diagnostic Read codes and test 
values were sourced. Obesity was defined using Read codes indicative of obesity and body mass index 
measurements (BMI≥30 kg/m2). Chronic kidney disease was defined using Read codes for stage 3 and above or 
an estimated glomerular filtration rate < 60 ml/min.  
 
 
Elevated HbA1c was defined as a value >7% (53mmol/mol) and >8% (64mmol/mol). These HbA1c levels were 
chosen as they correspond to the recommended HbA1c targets in the National Institute for Health and Care 
Excellence (NICE)  guidelines for management of type 2 diabetes.
5
 High blood pressure was defined as 
measurements >140/80mmHg or  >130/80mmHg in those with target organ damage. Hypercholesterolaemia 
was defined as total cholesterol>4mmol/L or LDL cholesterol>2mmol/L. 
 
Microalbuminuria was defined as an albumin:creatinine ratio (ACR) value of 3.5-30 mg/mmol in women and 
2.5-30 mg/mmol in men. Proteinuria was defined as an ACR value > 30 mg/mmol or a protein:creatinine ratio 
(PCR) value > 40 mg/mmol.  
 
Definition of baseline risk factor control 
Recorded HbA1c, blood pressure and cholesterol measurements were used to define risk factor control.  
 
Baseline hyperglycaemia (HbA1c >7% [53mmol/mol]), hypertension (blood pressure >140/80mmHg or 
>130/80mmHg for those with target organ damage) and hypercholesterolaemia (total cholesterol>4mmol/L or 
LDL cholesterol>2mmol/L) were defined as 2 consecutive test values above the threshold cut-offs, up to 6 
months before and 3 months after the index date (diabetes diagnosis date or corresponding index date for 
controls).  
 
The proportion of T2DM patients with missing data on risk factors at baseline was 17.8% for hyperglycaemia, 
29.5% for hypertension and 65.8% for elevated cholesterol.  
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Charlson Comorbidity Index (CCI) 
Comparison of original CCI to the CCI used in this study. Diabetes and cardiovascular conditions were excluded 
from the score.  
The CCI was defined at baseline using Read codes, up to the index date.  
 
Supplemental Table 1: Conditions included in CCI variable 
Original CCI CCI used in this study 
Comorbid condition Weight Comorbid condition Weight 
Myocardial infarction 1 - - 
Congestive heart failure 1 - - 
Peripheral vascular disease 1 - - 
Cerebrovascular disease 1 - - 
Dementia 1 Dementia 1 
Chronic pulmonary disease 1 Chronic pulmonary disease 1 
Connective tissue disease 1 Connective tissue disease 1 
Diabetes without complications 1 - - 
Peptic ulcer disease 1 Peptic ulcer disease 1 
Mild liver disease 1 Mild liver disease 1 
    
Hemiplegia 2 Hemiplegia 2 
Moderate or severe renal disease 2 Moderate or severe renal disease 2 
Diabetes with complications 2 - - 
Cancer 2 Cancer 2 
    
Moderate or severe liver disease 3 Moderate or severe liver disease 3 
    
Metastatic solid tumour 6 Metastatic solid tumour 6 
AIDS 6 AIDS 6 
 
 
 
Multiple Imputation 
Multiple imputation was implemented using the two-fold fully conditional specification algorithm to impute 
missing longitudinal data (annual measurements for obesity, hypertension, hypercholesterolaemia and raised 
HbA1c). This algorithm has been validated for use in electronic health care databases where the pattern of 
missing longitudinal data tends to be intermittent and potentially non-monotonic.
6,7
 Missing values at a specific 
time point are imputed from a model using information from that time point and immediately adjacent time 
points (default time window width is 1).
6,7
 This approach increases the plausibility of the missing at random 
assumption by using repeated measures over time.
5
 
 
Imputation models were estimated separately for men and women with a 2-year time window around missing 
data time points used. We implemented a time window width of 2 to increase the availability of information 
being used to impute missing values. In a simulation study this increase in time window width to 2 showed 
slight improvements in bias and precision compared to a time window width of 1.
8
 Data measurements past 2 
years were unlikely to provide substantial additional information. Factors included in the imputation model 
were: age, diabetes status, ethnicity, deprivation, calendar year, history of cardiovascular disease at index date, 
baseline measures of smoking status, obesity, HbA1c, hypertension and hypercholesterolaemia, longitudinal 
measures of smoking status, obesity, HbA1c, hypertension and hypercholesterolaemia and the cardiovascular 
outcome. Five imputed datasets were generated and combined.  
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Sensitivity Analyses 
Major cardiovascular event risk associated with diabetes 
Data was stratified into two time periods, diabetes diagnoses between 2007-2010 and 2011-2013 to allow for 
comparison between a time period close to the introduction and implementation of guidelines and QOF and a 
later period.  
 
Sex-specific hazard ratios were estimated from Cox proportional hazard models in both time periods for the 
primary (MI, stroke and cardiovascular death) and secondary outcomes (fatal/non-fatal MI and non-fatal stroke) 
in people with type 2 diabetes compared to controls without diabetes. Four models were applied; 1) unadjusted, 
2) adjusted for baseline calendar year, age, ethnicity, and deprivation, 3) additional adjustment for baseline 
smoking, obesity, hypertension, hypercholesterolaemia, and Charlson Comorbidity Index, and 4) further 
adjustment for time-varying smoking, obesity, hypertension, hypercholesterolaemia and raised HbA1c. 
 
Attainment of Standards of Care 
Prevalent CVD was expected to be greater in men and those with any history of CVD were likely to be treated 
more aggressively; therefore, we assessed for sex differences within type 2 diabetes groups with and without 
prevalent CVD for specific standards of care indicators to observe any treatment and management differences. 
This included the following indicators: “last measured total cholesterol levels below the recommended target of 
5 mmol/L”, “last blood pressure ≤140/80mmHg” and “treated with statins”. 
 
 
We also assessed for sex-related treatment bias in those aged <50 years and ≥50 years in part because some 
drugs with teratogenic effects are not recommended in women of child-bearing age. This related to the 
indicators: “treated with ACE inhibitors for microalbuminuria/proteinuria” and “treated with statins”. 
 
 
Multiple logistic regression models were used to assess sex differences in attainment of standard of care 
indicators within follow-up time bands.   
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Supplemental Tables 
 
Supplemental Table 2. Baseline clinical characteristics of people with type 2 diabetes at 
diagnosis by CVD status 
 
 
Data presented as N(%) or mean±SD * total cholesterol>4mmol/L or LDL cholesterol>2mmol/L 
† HbA1c <7% (53mmol/mol); BP < 130/80mmHg; lipids: total cholesterol<4mmol/L or LDL cholesterol<2mmol/L 
‡ Current use defined as prescriptions up to 90 days prior to index date 
 T2DM (N=79,985) 
Without CVD  (N=63,718) With CVD  (N=16,267) 
Women Men Women Men 
n, % 29,348 (46.1) 34,370 (54.0) 6,048 (37.2) 10,219 (62.8) 
Age, years 62.1±14.2 59.0±12.7 72.8±11.4 68.9±10.7 
Ethnicity         
White 22,700 (77.4) 25,452 (74.1) 5,390 (89.1) 9,069 (88.8) 
South Asian 1,402 (4.8) 1,534 (4.5) 142 (2.4) 258 (2.5) 
Black 714 (2.4) 668 (1.9) 70 (1.2) 80 (0.8) 
Other 368 (1.3) 442 (1.3) 32 (0.5) 65 (0.6) 
Unknown 4,164 (14.2) 6,274 (18.3) 414 (6.9) 747 (7.3) 
Deprivation         
IMD 1 (least deprived) 5,390 (18.4) 6,925 (20.2) 940 (15.5) 1,885 (18.5) 
IMD 2 6,288 (21.4) 7,884 (22.9) 1,336 (22.1) 2,341 (22.9) 
IMD 3 5,915 (20.2) 6,970 (20.3) 1,148 (19.0) 2,069 (20.3) 
IMD 4 6,284 (21.4) 6,894 (20.1) 1,330 (22.0) 2,067 (20.2) 
IMD 5 (most deprived) 5,426 (18.5) 5,666 (16.5) 1,282 (21.2) 1,844 (18.0) 
Unknown 45 (0.2) 31 (1.0) 12 (0.2) 13 (0.1) 
Obese 15,879 (54.1) 17,395 (50.6) 2,638 (43.6) 4,616 (45.2) 
Smoking         
Current 8,698 (29.5) 14,617 (42.5) 2,505 (41.4) 6,266 (61.3) 
Ex-smoker 8,285 (28.3) 9,182 (26.7) 1,638 (27.1) 2,382 (23.3) 
Never  1,692 (5.8) 1,218 (3.5) 300 (5.0) 250 (2.5) 
Unknown 10,673 (36.4) 9,353 (27.2) 1,605 (26.5) 1,321 (12.9) 
HbA1c >7% (53mmol/mol) 13,413 (45.7) 17,604 (51.2) 2,406 (39.8) 4,263 (41.7) 
HbA1c >8% (64mmol/mol) 7,733 (26.4) 11,490 (33.4) 1,111 (18.4) 2,109 (20.6) 
BP>140/80 mmHg 9,281 (31.6) 12,025 (35.0) 1,401 (23.2) 2,174 (21.3) 
BP>130/80 mmHg 13,208 (45.0) 15,978 (46.5) 2,369 (39.2) 3,660 (35.8) 
with target organ damage 3,009 (10.3) 1,889 (5.5) 1,528 (25.3) 1,771 (17.3) 
Hypercholesterolaemia*  7,709 (26.3) 8,406 (24.5) 1,264 (20.9) 1,838 (18.0) 
Risk factors in control †         
1 RF in control 12,024 (41.0) 13,223 (38.5) 2,585 (42.7) 4,305 (42.1) 
2 RF in control 3,711 (12.6) 3,689 (10.7) 1,105 (18.3) 2,126 (20.8) 
3 RF in control 326 (1.1) 419 (1.2) 178 (2.9) 399 (3.9) 
Cardiovascular disease - - 6,048 (100.0) 10,219 (100.0) 
Coronary heart disease - - 3,910 (64.7) 7,506 (73.5) 
Cerebrovascular disease - - 2,175 (36.0) 2,737 (26.8) 
Peripheral vascular disease - - 946 (15.6) 1,808 (17.7) 
Chronic kidney disease 5,474 (18.7) 3,302 (9.6) 2,447 (40.5) 2,672 (26.2) 
Microalbuminuria or 
proteinuria 
2,653 (9.0) 4,318 (12.6) 763 (12.6) 1,605 (15.7) 
Peripheral neuropathy 241 (0.8) 331 (1.0) 102 (1.7) 196 (1.9) 
Retinopathy 1,023 (3.5) 1,334 (3.9) 255 (4.2) 491 (4.8) 
History of pregnancy 9,055 (30.9) - 1,257 (20.8) - 
Hormone-replacement 
therapy (current use) ‡ 
396 (1.4) - 55 (0.9) - 
Oral contraceptives 
(current use )‡ 
391 (1.3) - 6 (0.1) - 
5 
 
 
Supplemental Table 3. Overall and sex-specific cardiovascular incidence rates in patients with type 2 diabetes and controls 
 
 
 
T2DM (N=79,985) Controls (N=386,547) 
All Women (N=35,396) Men (N=44,589) All Women (N=172,994) Men (N=213,553) 
n IR (95% CI)  n IR (95% CI) n IR (95% CI) n IR (95% CI) n IR (95% CI) n IR (95% CI) 
Including individuals with prevalent CVD 
MACE 9,806 32.6 
(31.9-33.2) 
4,091 30.5 
(29.6-31.5) 
5,715 34.2 
(33.3-35.1) 
30,226 22.0 
(21.7-22.2) 
12,850 20.4 
(20.0-20.7) 
17,376 23.4 
(23.0-23.7) 
    MI*       6,697 22.2 
(21.7-22.8) 
2,640 19.7 
(19.0-20.5) 
4,057 25.3 
(23.5-25.0) 
17,883 13.0 
(12.8-13.2) 
7,063 11.2 
(10.9-11.5) 
10,820 14.5 
(14.3-14.8) 
   Stroke* 2,016 6.7 
(6.4-7.0) 
963 7.2 
(6.7-7.7) 
1,053 6.3 
(5.9-6.7) 
7,756 5.6 
(5.5-5.8) 
3,750 5.9 
(5.8-6.1) 
4,006 5.4 
(5.2-5.6) 
  Non-fatal MI 6,453 21.4 
(20.9-22.0) 
2,558 19.1 
(18.4-19.9) 
3,895 23.3 
(22.6-24.1) 
16,999 12.4 
(12.2-12.5) 
6,735 10.7 
(10.4-10.9) 
10,264 13.8 
(13.5-14.1) 
Excluding individuals with prevalent CVD 
MACE 4,564 18.2  
(17.6-18.7) 
2,042 17.6 
(16.8-18.3) 
2,522 18.7 
(18.0-19.4) 
11,665 11.4 
 (11.2-11.6) 
5,364 10.9  
(10.6-11.2) 
6,301 11.9 
(11.6-12.2) 
    MI*       2,697 10.7 
 (10.3-11.1) 
1,118 9.6 
(9.1-10.2) 
1,579 11.7 
(11.1-12.3) 
6,111 6.0 
(5.8-6.1) 
2,524 5.1 
(4.9-5.3) 
3,587 6.8 
(6.6-7.0) 
   Stroke* 1,230 4.9 
(4.6-5.2) 
621 5.3 
(4.9-5.8) 
609 4.5 
(4.2-4.9) 
3,641 3.6 
(3.5-3.7) 
1,912 3.9  
(3.7-4.1) 
1,729 3.3 
(3.1-3.4) 
  Non-fatal MI 2,560 10.2  
(9.8-10.6) 
1,061 9.1 
(8.6-9.7) 
1,499 11.1 
(10.5-11.7) 
5,693 5.6 
 (5.4-5.7) 
2,365 4.8 
(4.6-5.0) 
3,328 6.3 
(6.1-6.5) 
 
IR (incidence rate per 1,000 person-years) 
* fatal and non-fatal events 
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Supplemental Table 4. Unadjusted and multivariable-adjusted hazard ratios for incident CVD comparing people with and without T2DM by 
sex, including the ratio of risks (RRR) between women and men showing the excess risk for incident CVD in women 
 
 
Ratio of relative risks (RRR) greater than 1 indicates an excess risk for incident cardiovascular disease in women who developed diabetes compared to men who developed diabetes
Model Adjustments 
 Primary Outcome: MACE Secondary Outcome: MI  
(fatal/non-fatal) 
Secondary Outcome: non-fatal MI  Secondary Outcome: Stroke 
(fatal/non-fatal) 
Risk of CV 
associated with 
the presence of 
diabetes;  
HR (95% CI) 
Ratio of risks 
between 
 women and  
men; 
RRR (95% CI) 
Risk of CV 
associated with 
the presence of 
diabetes;  
HR (95% CI) 
Ratio of risks 
between 
 women and  
men; 
RRR (95% CI) 
Risk of CV 
associated with 
the presence of 
diabetes;  
HR (95% CI) 
Ratio of risks 
between 
 women and  
men; 
RRR (95% CI) 
Risk of CV 
associated with 
the presence of 
diabetes;  
HR (95% CI) 
Ratio of risks 
between 
 women and 
men; 
RRR (95% CI) 
1 Unadjusted Women 1.44 (1.36-1.52) 
1.05 (0.98-1.13) 
1.68 (1.56-1.81) 
1.09 (0.99-1.20) 
1.82 (1.70-1.96) 
1.08 (0.98-1.18) 
1.24 (1.13-1.37) 
1.06 (0.92-1.22) 
Men 1.37 (1.31-1.44) 1.54 (1.45-1.64) 1.69 (1.59-1.79) 1.17 (1.06-1.30) 
2 Calendar year,  age, 
ethnicity, deprivation, 
general practice 
Women 1.36 (1.29-1.44) 
1.08 (1.00-1.16) 
1.55 (1.44-1.67) 
1.12 (1.01-1.23) 
1.66 (1.55-1.79) 
1.09 (0.99-1.20) 
1.18 (1.07-1.30) 
1.04 (0.93-1.18) 
Men 1.26 (1.20-1.33) 1.39 (1.30-1.48) 1.52 (1.43-1.61) 1.13 (1.05-1.21) 
3 Model 2 plus baseline 
smoking, obesity, 
hypertension,  
hypercholesterolaemia, 
and CCI 
Women 1.23 (1.16-1.32)  
1.05 (0.97-1.14)  
1.35 (1.24-1.48)  
1.07 (0.95-1.20)  
1.45 (1.34-1.58)  
1.05 (0.94-1.17)  
1.15 (1.03-1.28) 
1.06 (0.93-1.22) 
Men 1.17 (1.11-1.23)  1.26 (1.17-1.36)  1.38 (1.29-1.48)  1.08 (1.00-1.17) 
4 Model 3 plus time-
varying smoking, 
obesity, hypertension,   
hypercholesterolaemia 
and raised HbA1c 
Women 1.20 (1.12-1.28)  
1.07 (0.98-1.17)  
1.31 (1.20-1.43)  
1.09 (0.98-1.22)  
1.40 (1.29-1.53)  
1.06 (0.95-1.18)  
1.13 (1.01-1.26)  
1.09 (0.93-1.28)  
Men 1.12 (1.06-1.19)  1.20 (1.12-1.28)  1.32 (1.23-1.41)  1.04 (0.92-1.16)  
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Supplemental Table 5. Unadjusted and multivariable-adjusted hazard ratios for incident CVD comparing people with and without 
T2DM by sex, including the ratio of risks (RRR) between women and men showing the excess risk for incident CVD in women stratified 
by year of diagnosis (2007-2010) 
 
 
 
Ratio of relative risks (RRR) greater than 1 indicates an excess risk for incident cardiovascular disease in women who developed diabetes compared to men who developed diabetes 
Model Adjustments 
 Primary Outcome: MACE Secondary Outcome: MI  
(fatal/non-fatal) 
Secondary Outcome: Stroke (fatal/non-
fatal) 
Risk of CV 
associated with the 
presence of diabetes;  
HR (95% CI) 
Ratio of risks 
between 
 women and men; 
RRR (95% CI) 
Risk of CV 
associated with the 
presence of diabetes;  
HR (95% CI) 
Ratio of risks 
between 
 women and men; 
RRR (95% CI) 
Risk of CV 
associated with the 
presence of diabetes;  
HR (95% CI) 
Ratio of risks 
between 
 women and men; 
RRR (95% CI) 
1 Unadjusted Women 1.46 (1.36-1.58) 
1.07 (0.96-1.18) 
1.77 (1.60-1.96) 
1.17 (1.03-1.34) 
1.20 (1.05-1.37) 
0.96 (0.80-1.16) 
Men 1.37 (1.28-1.47) 1.51 (1.39-1.65) 1.25 (1.10-1.43) 
2 Calendar year,  age, 
ethnicity, deprivation, 
general practice 
Women 1.38 (1.28-1.48) 
1.10 (0.99-1.21) 
1.64 (1.48-1.82) 
1.22 (1.07-1.40) 
1.12 (0.98-1.28) 
0.97 (0.80-1.17) 
Men 1.26 (1.18-1.35) 1.34 (1.23-1.47) 1.16 (1.02-1.33) 
3 Model 2 plus baseline 
smoking, obesity, 
hypertension,   
hypercholesterolaemia, 
and CCI 
Women 1.26 (1.16-1.38) 
1.08 (0.96-1.21) 
1.44 (1.28-1.62) 
1.16 (0.99-1.36) 
1.12 (0.96-1.30) 
1.01 (0.82-1.25) 
Men 1.17 (1.08-1.27) 1.24 (1.12-1.38) 1.11 (0.96-1.29) 
4 Model 3 plus time-
varying smoking, obesity, 
hypertension,   
hypercholesterolaemia 
and raised HbA1c 
Women 1.22 (1.12-1.33) 
1.09 (0.97-1.22) 
1.39 (1.24-1.57) 
1.19 (1.01-1.39) 
1.09 (0.94-1.27) 
1.00 (0.82-1.23) 
Men 1.12 (1.04-1.20) 1.17 (1.05-1.30) 1.09 (0.95-1.25) 
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Supplemental Table 6. Unadjusted and multivariable-adjusted hazard ratios for incident CVD comparing people with and without 
T2DM by sex, including the ratio of risks (RRR) between women and men showing the excess risk for incident CVD in women stratified 
by year of diagnosis (2011-2013) 
 
 
 
Ratio of relative risks (RRR) greater than 1 indicates an excess risk for incident cardiovascular disease in women who developed diabetes compared to men who developed diabetes 
Model Adjustments 
 Primary Outcome: MACE Secondary Outcome: MI  
(fatal/non-fatal) 
Secondary Outcome: Stroke (fatal/non-
fatal) 
Risk of CV 
associated with the 
presence of diabetes;  
HR (95% CI) 
Ratio of risks 
between 
 women and men; 
RRR (95% CI) 
Risk of CV 
associated with the 
presence of diabetes;  
HR (95% CI) 
Ratio of risks 
between 
 women and men; 
RRR (95% CI) 
Risk of CV 
associated with the 
presence of diabetes;  
HR (95% CI) 
Ratio of risks 
between 
 women and men; 
RRR (95% CI) 
1 Unadjusted Women 1.52 (1.32-1.75) 
0.95 (0.79-1.14) 
1.67 (1.37-2.03) 
0.94 (0.73-1.20) 
1.61 (1.28-2.02) 
1.29 (0.93-1.79) 
Men 1.60 (1.42-1.80) 1.78 (1.53-2.07) 1.25 (0.99-1.58) 
2 Calendar year, age, 
ethnicity, deprivation, 
general practice 
Women 1.45 (1.25-1.67) 
1.00 (0.83-1.21) 
1.52 (1.24-1.86) 
0.97 (0.75-1.26) 
1.60 (1.27-2.03) 
1.36 (0.97-1.90) 
Men 1.45 (1.28-1.64) 1.56 (1.33-1.82) 1.18 (0.93-1.50) 
3 Model 2 plus baseline 
smoking, obesity, 
hypertension,   
hypercholesterolaemia, 
and CCI 
Women 1.31 (1.11-1.53) 
0.94 (0.76-1.17) 
1.38 (1.10-1.72) 
0.97 (0.72-1.31) 
1.43 (1.11-1.85) 
1.15 (0.79-1.69) 
Men 1.39 (1.20-1.60) 1.42 (1.17-1.72) 1.24 (0.93-1.64) 
4 Model 3 plus time-varying 
smoking, obesity, 
hypertension,   
hypercholesterolaemia and 
raised HbA1c 
Women 1.27 (1.07-1.49) 
0.94 (0.75-1.18) 
1.33 (1.04-1.68) 
0.98 (0.72-1.33) 
1.41 (1.07-1.84) 
1.13 (0.74-1.72) 
Men 1.35 (1.16-1.58) 1.36 (1.12-1.66) 1.25 (0.90-1.73) 
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Supplemental Table 7. Unadjusted and multivariable-adjusted hazard ratios for incident MACE events comparing people with and 
without T2DM by sex and age of onset of T2DM  
 
 
Ratio of relative risks (RRR) greater than 1 indicates an excess risk for incident cardiovascular disease in women who developed diabetes compared to men who developed diabetes  
  
 
 
 
Model 
 
 
Adjustments 
 Primary Outcome: MACE 
<50 years 
 
T2DM: N=14,049 
Controls: N=69,416 
50-60 years 
 
T2DM: N=15,587 
Controls: N=73,962 
60-70 years 
 
T2DM: N=17,190 
Controls: N=74,652 
≥70 years 
 
T2DM: N=16,892 
Controls: N=59,146 
Risk of CV 
associated with the 
presence of diabetes;  
HR (95% CI) 
Ratio of risks 
between women 
and men; 
RRR (95% CI) 
Risk of CV 
associated with the 
presence of diabetes;  
HR (95% CI) 
Ratio of risks 
between women 
and men; 
RRR (95% CI) 
Risk of CV 
associated with the 
presence of diabetes;  
HR (95% CI) 
Ratio of risks 
between women 
and men; 
RRR (95% CI) 
Risk of CV 
associated with the 
presence of diabetes;  
HR (95% CI) 
Ratio of risks 
between women 
and men; 
RRR (95% CI) 
 
1 
Unadjusted Women 3.73 (2.92-4.78) 
1.39 (1.03-1.87) 
2.10 (1.78-2.48) 
1.21 (1.00-1.48) 
1.74 (1.55-1.94) 
1.39 (1.21-1.60) 
1.19 (1.11-1.28) 
1.04 (0.94-1.16) 
Men 2.69 (2.28-3.18) 1.73 (1.56-1.93) 1.25 (1.15-1.37) 1.14 (1.05-1.23) 
2 Calendar year, 
ethnicity, deprivation, 
general practice 
Women 3.33 (2.56-4.31) 
1.41 (1.03-1.93) 
2.03 (1.70-2.42) 
1.33 (1.08-1.63) 
1.57 (1.40-1.76) 
1.38 (1.19-1.59) 
1.14 (1.06-1.23) 
1.05 (0.94-1.17) 
Men 2.36 (1.98-2.80) 1.53 (1.37-1.71) 1.14 (1.04-1.25) 1.09 (1.01-1.19) 
3 Model 2 plus baseline 
smoking, obesity, 
hypertension,  
hypercholesterolaemia 
and CCI 
Women 3.02 (2.11-4.34) 
1.31 (0.87-1.99) 
1.69 (1.36-2.10) 
1.22 (0.95-1.57) 
1.41 (1.24-1.60) 
1.34 (1.14-1.58) 
1.06 (0.98-1.15) 
1.05 (0.93-1.19) 
Men 2.30 (1.87-2.82) 1.38 (1.22-1.57) 1.05 (0.95-1.16) 1.01 (0.92-1.11) 
4 Model 3 plus time-
varying smoking, 
obesity, hypertension,   
hypercholesterolaemia 
and raised HbA1c 
Women 2.83 (1.86-4.30) 
1.30 (0.80-2.09) 
1.67 (1.35-2.08) 
1.26 (0.98-1.61) 
1.38 (1.22-1.56) 
1.35 (1.15-1.60) 
1.04 (0.95-1.12) 
1.04 (0.92-1.18) 
Men 2.18 (1.73-2.74) 1.33 (1.17-1.51) 1.02 (0.89-1.11) 1.00 (0.90-1.08) 
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Supplemental Table 8. Comparisons between women and men of the proportion and rate of risk factor checks, risk factor levels, 
interventions, and prescriptions from the diagnosis of T2DM up to 7 years after diagnosis 
 
Risk factor checks, levels, interventions 
and prescriptions 
Year 1 Years 2-3 Years 4-5 Years 6-7 
Women Men Women Men Women Men Women Men 
n (%) 35,396 
(44.3) 
44,589 
(55.8) 
24,957 
(44.3) 
31,352 
(55.7) 
14,996 
(44.6) 
18,667 
(55.5) 
7,614 
(45.1) 
9,257 
(54.9) 
No. of consultations/person/year          
Face-to-face interactions 15 13 10 7 10 8 10 8 
Telephone interactions 1.1 0.8 0.7 0.5 0.8 0.6 0.8 0.6 
No. of risk factor checks/person/year          
HbA1c tests 2.09 2.04 1.32 1.26 1.28 1.24 1.28 1.24 
Blood pressure checks 3.49 3.32 2.04 1.82 1.92 1.77 1.82 1.70 
Lipids checks 1.75 1.80 1.01 0.99 0.96 0.96 0.92 0.94 
BMI measured 2.67 2.37 1.44 1.21 1.33 1.18 1.25 1.14 
Smoking cessation discussed 0.50 0.52 0.32 0.31 0.31 0.32 0.29 0.32 
Risk factors levels          
HbA1c >7% (53mmol/mol), % 54.1 57.9 46.5 50.3 49.3 52.8 48.6 51.6 
HbA1c >8% (64mmol/mol), % 30.0 35.8 22.5 26.0 25.6 28.7 26.6 29.0 
         
Blood pressure >140/80, % 53.8 53.5 44.0 43.2 37.9 37.2 30.0 29.3 
     On BP medication 79.8 76.7 84.5 83.4 86.5 85.7 88.9 87.6 
         
Blood pressure >130/80, % 67.7 66.7 59.5 58.6 54.6 53.9 47.0 46.0 
      On BP medication 78.2 75.1 82.7 81.4 84.7 83.3 87.3 85.6 
         
Blood pressure >130/80 and end organ 
damage, % 
25.0 15.8 26.9 19.4 27.2 20.6 26.1 19.4 
     On BP medication 90.7 90.4 90.9 89.6 90.8 89.4 92.1 90.4 
         
Cholesterol >target (LDL>2 or TC>4), % 55.6 48.5 45.7 36.0 38.1 28.8 29.8 21.5 
     On lipid-lowering medication 70.0 69.8 76.0 74.8 75.6 76.9 76.3 77.6 
         
Obese, % 57.0 54.1 50.5 46.8 48.0 44.3 42.4 40.0 
         
Current smoking, % 13.9 15.5 11.8 12.9 10.8 11.6 9.1 10.3 
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Risk factor checks, levels, interventions 
and prescriptions 
Year 1 Years 2-3 Years 4-5 Years 6-7 
Women  Men Women Men Women Men Women Men 
n (%) 35,396 
(44.3) 
 44,589 
(55.8) 
24,957 
(44.3) 
31,352 
(55.7) 
14,996 
(44.6) 
18,667 
(55.5) 
7,614 
(45.1) 
9,257  
(54.9) 
Interventions          
Diet intervention offered, % 59.7 60.0 51.0 50.6 53.8 54.9 64.5 63.2 
Exercise intervention offered, % 43.1 44. 39.0 39.1 37.5 38.0 33.4 33.2 
Structured education offered, % 16.6 17.0 3.1 3.3 4.0 4.5 5.7 6.8 
Bariatric surgery, % 0.14 0.03 0.21 0.09 0.12 0.06 0.17 0.04 
Drug Prescriptions          
Diabetes         
Any oral hypoglycaemic agent, % 57.7 59.0 67.9 70.4 72.8 75.9 76.0 79.1 
  Metformin, % 52.2 53.5 60.7 64.2 64.0 68.7 66.1 71.2 
  Sulphonylurea, % 13.7 14.3 20.6 23.0 26.0 29.2 28.9 33.2 
  Glitazone, % 2.1 2.0 3.9 4.3 4.8 5.5 5.0 6.1 
  DPP4i, % 1.6 1.5 6.9 6.9 10.8 11.6 13.6 15.3 
  SGLT2i, % 0.1 0.1 0.4 0.4 0.9 0.9 1.9 1.9 
  GLP-1 agonist, % 0.3 0.2 2.0 1.5 3.5 2.7 4.2 3.5 
  Meglitinide, % 0.2 0.2 0.3 0.3 0.3 0.3 0.4 0.3 
  Insulin, % 4.4 4.2 5.5 4.8 7.5 6.4 9.9 9.1 
  Combination, % 0.6 0.8 1.1 1.5 1.2 1.8 1.2 1.7 
         
Antihypertensive agent         
  Any, % 69.4 66.7 72.3 71.0 74.5 73.8 76.4 75.7 
  Alpha-blocker, % 5.3 6.4 6.4 7.9 6.9 8.5 7.4 8.9 
  Angiotensin II receptor blocker, % 15.0 11.7 17.8 14.4 19.5 15.5 20.4 16.4 
  ACE inhibitor, % 37.1 42.9 39.7 47.1 40.6 49.2 41.8 50.1 
  Beta-blocker, % 21.8 23.1 20.6 22.0 20.5 21.8 20.7 21.5 
  Calcium channel blocker, % 28.4 28.8 30.5 31.9 31.7 33.3 33.0 34.8 
  Diuretic: thiazide, potassium     
  sparing or loop, % 
36.9 24.8 34.3 23.9 34.7 24.6 34.0 24.4 
         
Lipid lowering therapy         
  Any, % 66.5 70.4 73.8 75.9 75.2 78.2 76.3 79.5 
  Statin, % 65.2 69.1 71.8 74.5 73.0 76.4 73.7 77.5 
  Fibrate, % 1.2 1.6 1.7 2.0 1.7 2.2 1.9 2.3 
  Ezetimibe, % 4.1 3.6 4.8 4.0 5.2 4.3 5.7 4.4 
  Other, % 2.7 2.9 3.9 3.5 3.7 3.4 3.6 3.0 
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Data presented as %,or age-adjusted rate, as indicated 
 
% missing data for risk factor levels; 
HbA1c: Baseline 4.2% (women 4.3%, men 4.1%), Years 2-3 11.5% (women 11.3%, men 11.6%); Years 4-5 13.9% (women 14.1%, men 13.7%); Years 6-7 18.8% (women 18.7%, men 18.9%) 
Blood Pressure: Baseline 2.3% (women 2.3%, men 2.2%), Years 2-3 9.7% (women 9.2%, men 10.1%); Years 4-5 12.1% (women 11.9%, men 12.3%); Years 6-7 16.9% (women 16.2%, men 17.4%) 
Cholesterol: Baseline 4.6% (women 5.1%, men 4.1%), Years 2-3 13.2% (women 13.0%, men 13.4%); Years 4-5 16.0% (women 16.2%, men 15.9%); Years 6-7 22.0% (women 22.0%, men 22.1%) 
Obesity: Baseline 6.9% (women 7.7%, men 6.3%), Years 2-3 15.1% (women 15.3%, men 14.9%); Years 4-5 17.9% (women 18.2%, men 17.5%); Years 6-7 24.4% (women 24.8%, men 24.1%) 
 
 
 
 
 
 
 
 
 
 
 
 
Risk factor checks, levels, interventions 
and prescriptions 
Year 1 Years 2-3 Years 4-5 Years 6-7 
Women Men Women Men Women Men Women Men 
n (%) 35,396 
(44.3) 
44,589  
(55.8) 
24,957 
(44.3) 
31,352 
(55.7) 
14,996 
(44.6) 
18,667 
(55.5) 
7,614 
(45.1) 
9,257 
(54.9) 
Antiplatelets         
  Any, % 30.5 36.2 30.3 36.3 29.0 35.6 28.8 35.9 
  Aspirin, % 28.8 34.4 28.6 34.4 27.2 33.6 26.6 33.7 
  Clopidogrel, % 3.6 4.9 3.0 4.2 3.1 4.0 3.6 3.9 
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Supplemental Table 9. Comparisons between women and men of risk factor checks, risk factor levels, interventions, and prescriptions 
from the diagnosis of T2DM to 7 years after diagnosis – analysis stratified by CVD status (with CVD from baseline and through follow-
up) 
 
Risk factor checks, levels, interventions 
and prescriptions 
Year 1 Years 2-3 Years 4-5 Years 6-7 
Women 
N=35,396 
Men 
N=44,589 
Women 
N=24,957 
Men 
N=31,352 
Women 
N=14,996 
Men 
N=18,667 
Women 
N=7,614 
Men 
N=9,257 
n (%) 6,587 
 (18.6) 
10,897  
(24.4) 
3,939  
(15.8) 
6,871 
 (21.9) 
2,115 
 (14.1) 
3,723 
 (19.9) 
945 
 (12.4) 
1,657  
(17.9) 
No. of consultations/person/year     
Face-to-face interactions 21 15 14 8 12 9 13 9 
Telephone interactions 2.1 0.8 1.7 0.5 0.7 0.6 0.6 0.6 
No. of risk factor checks/person/year     
HbA1c tests  2.06 1.96 1.47 1.13 1.23 1.16 1.40 1.22 
Blood pressure checks 4.15 3.67 2.51 2.14 2.20 2.46 2.55 1.91 
Lipids checks 2.05 1.79 1.26 1.01 0.99 0.94 0.98 0.97 
BMI measured 2.83 2.37 1.46 1.28 1.35 1.17 0.28 1.01 
Smoking cessation discussed 0.83 0.77 0.86 0.31 0.35 0.29 0.58 0.28 
Risk factors levels     
HbA1c >7% (53mmol/mol), % 49.4 52.0 41.7 46.8 44.4 47.4 45.1 47.0 
HbA1c >8% (64mmol/mol), % 23.9 26.5 18.7 21.3 21.4 23.4 23.5 23.4 
         
Blood pressure >140/80, % 47.8 45.3 42.9 40.0 37.5 34.0 32.6 28.3 
      On BP medication 94.7 93.3 95.2 95.3 93.8 95.7 96.4 95.5 
Blood pressure >130/80, % 64.1 62.3 58.6 57.5 54.7 52.2 50.3 47.1 
      On BP medication 94.3 92.8 94.9 94.2 93.3 94.5 95.8 94.2 
         
Cholesterol >target (LDL>2 or TC>4), % 43.3 35.8 39.8 30.9 32.4 24.5 26.4 19.5 
     On lipid-lowering medication 84.6 88.3 86.7 89.0 84.4 87.9 79.1 87.9 
         
Obese, % 47.3 49.4 41.1 43.6 39.5 39.5 35.8 36.8 
         
Current smoking, % 13.1 13.7 12.1 12.1 10.5 11.8 9.6 10.7 
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Risk factor checks, levels, interventions 
and prescriptions 
Year 1 Years 2-3 Years 4-5 Years 6-7 
Women 
N=35,396 
Men 
N=44,589 
Women 
N=24,957 
Men 
N=31,352 
Women 
N=14,996 
Men 
N=18,667 
Women 
N=7,614 
Men 
N=9,257 
n (%) 6,587  
(18.6) 
10,897 
 (24.4) 
3,939 
 (15.8) 
6,871 
 (21.9) 
2,115  
(14.1) 
3,723 
 (19.9) 
945 
 (12.4) 
1,657  
(17.9) 
Interventions     
Diet intervention offered, % 55.8 59.4 47.9 50.7 49.7 54.0 61.7 62.7 
Exercise intervention offered, % 41.5 46.7 37.7 41.0 37.3 39.6 33.4 35.1 
Structured education offered, % 13.9 16.0 2.6 2.6 2.7 3.8 4.4 6.0 
Bariatric surgery, % 0.05 0.00 0.03 0.07 0.00 0.00 0.11 0.06 
Drug Prescriptions     
Diabetes         
  Any oral hyoglycaemic agent, % 53.4 55.8 61.1 66.5 65.9 72.0 70.6 75.9 
  Metformin, % 44.6 47.9 50.8 58.1 53.7 61.8 57.9 65.0 
  Sulphonylurea, % 15.4 14.9 20.8 21.7 25.8 27.8 26.9 31.7 
  Glitazone, % 2.0 1.5 3.1 3.1 3.6 3.7 3.8 4.2 
  DPP4i, % 1.3 1.1 4.7 5.4 7.6 9.7 9.8 13.8 
  SGLT2i, % 0.1 0.1 0.2 0.2 0.4 0.6 0.4 0.8 
  GLP-1 agonist, % 0.2 0.2 1.0 1.2 1.6 2.0 1.9 3.0 
  Meglitinide, % 0.2 0.2 0.3 0.4 0.2 0.3 0.3 0.3 
  Insulin, % 5.4 5.4 6.0 5.4 8.0 7.0 11.2 9.0 
  Combination, % 0.5 0.6 0.8 1.1 0.6 1.2 0.2 1.2 
         
Antihypertensive agent         
  Any, % 90.9 91.0 90.2 90.1 89.5 90.4 91.4 90.0 
  Alpha-blocker, % 7.4 8.3 8.7 9.9 9.0 10.0 8.0 10.3 
  Angiotensin II receptor blocker, % 20.9 16.4 22.8 17.7 22.9 18.1 25.2 19.0 
  ACE inhibitor, % 47.1 57.6 49.0 58.3 47.2 59.5 47.6 58.4 
  Beta-blocker, % 43.1 52.3 42.3 50.5 41.8 48.7 43.5 48.6 
  Calcium channel blocker, % 40.1 37.8 41.8 39.8 40.9 39.8 43.8 41.3 
  Diuretic: thiazide, potassium     
  sparing or loop, % 
54.7 39.0 50.8 37.1 51.2 37.3 49.0 36.6 
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Risk factor checks, levels, interventions 
and prescriptions 
Year 1 Years 2-3 Years 4-5 Years 6-7 
Women 
N=35,396 
Men 
N=44,589 
Women 
N=24,957 
Men 
N=31,352 
Women 
N=14,996 
Men 
N=18,667 
Women 
N=7,614 
Men 
N=9,257 
n (%) 6,587 
 (18.6) 
10,897 
 (24.4) 
3,939 
 (15.8) 
6,871 
 (21.9) 
2,115  
(14.1) 
3,723  
(19.9) 
945 
 (12.4) 
1,657  
(17.9) 
Lipid lowering therapy         
  Any, % 83.5 89.6 83.7 88.6 82.4 87.9 82.8 88.1 
  Statin, % 81.5 88.0 81.0 86.9 79.8 85.9 79.3 86.1 
  Fibrate, % 1.8 2.2 2.4 2.6 2.4 2.8 3.2 2.8 
  Ezetimibe, % 7.0 6.4 8.0 6.8 8.2 6.5 9.2 6.6 
  Other, % 5.3 6.5 6.6 6.1 5.7 5.5 5.8 5.0 
         
Antiplatelets         
  Any, % 69.6 75.4 66.7 74.1 65.8 73.1 65.6 72.4 
  Aspirin, % 62.8 69.6 60.3 68.3 58.6 66.8 57.4 65.7 
  Clopidogrel, % 15.4 17.5 12.8 14.7 14.0 14.3 14.6 13.3 
 
Data presented as %,or age-adjusted rate, as indicated 
 
 
 
 
 
 
 
 
 
 
16 
 
Supplemental Table 10. Comparisons between women and men of risk factor checks, risk factor levels, interventions, and prescriptions 
from the diagnosis of T2DM to 7 years after diagnosis – analysis stratified by CVD status (without CVD from baseline and through 
follow-up) 
 
Risk factor checks, levels, interventions 
and prescriptions 
Year 1 Years 2-3 Years 4-5 Years 6-7 
Women 
N=35,396 
Men 
N=44,589 
Women 
N=24,957 
Men 
N=31,352 
Women 
N=14,996 
Men 
N=18,667 
Women 
N=7,614 
Men 
N=9,257 
n (%) 28,809 
 (81.4) 
33,692 
 (75.6) 
21,018 
 (84.2) 
24,481 
 (78.1) 
12,881 
 (85.9) 
14,944 
 (80.1) 
6,669 
 (87.6) 
7,600  
(82.1) 
No. of consultations/person/year         
Face-to-face interactions 15 13 10 8 10 8 10 8 
Telephone interactions 1.0 0.7 0.7 0.5 0.7 0.6 0.8 0.5 
No. of risk factor checks/person/year         
HbA1c tests  2.07 2.01 1.30 1.24 1.27 1.23 1.26 1.22 
Blood pressure checks 3.42 3.24 2.00 1.76 1.88 1.71 1.78 1.65 
Lipids checks 1.73 1.77 0.99 0.97 0.95 0.94 0.91 0.93 
BMI measured 2.65 2.34 1.43 1.19 1.32 1.15 1.25 1.12 
Smoking cessation discussed 0.48 0.49 0.31 0.29 0.30 0.31 0.28 0.31 
Risk factors levels         
HbA1c >7% (53mmol/mol), % 55.1 59.8 47.4 51.2 50.1 54.1 49.1 52.6 
HbA1c >8% (64mmol/mol), % 31.4 38.8 23.2 27.4 26.3 30.1 27.0 30.2 
         
Blood pressure >140/80, % 55.1 56.1 44.2 44.2 38.0 38.0 29.7 29.5 
      On BP medication 76.9 72.4 82.6 80.3 85.3 83.5 87.7 86.0 
Blood pressure >130/80, % 68.5 68.1 59.7 59.0 54.6 54.4 46.6 45.8 
      On BP medication 74.7 69.8 80.5 77.9 83.3 80.7 86.0 83.7 
         
Cholesterol >target (LDL>2 or TC>4), % 58.4 52.5 46.8 37.4 39.1 29.9 30.3 22.0 
     On lipid-lowering medication 67.5 65.8 74.2 71.6 74.4 74.6 76.0 75.5 
         
Obese, % 59.2 55.6 52.2 47.8 49.4 45.5 43.4 40.7 
         
Current smoking, % 14.1 16.1 11.8 13.2 10.9 11.6 9.0 10.3 
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Risk factor checks, levels, interventions 
and prescriptions 
Year 1 Years 2-3 Years 4-5 Years 6-7 
Women 
N=35,396 
Men 
N=44,589 
Women 
N=24,957 
Men 
N=31,352 
Women 
N=14,996 
Men 
N=18,667 
Women 
N=7,614 
Men 
N=9,257 
n (%) 28,809  
(81.4) 
33,692 
 (75.6) 
21,018 
 (84.2) 
24,481 
 (78.1) 
12,881 
 (85.9) 
14,944 
 (80.1) 
6,669  
(87.6) 
7,600 
 (82.1) 
Interventions         
Diet intervention offered, % 60.5 60.1 51.6 50.6 54.5 55.1 64.9 63.3 
Exercise intervention offered, % 43.4 43.2 39.2 38.6 37.5 37.6 33.3 32.8 
Structured education offered, % 17.2 17.3 3.2 3.5 4.2 4.7 5.9 7.0 
Bariatric surgery, % 0.16 0.04 0.24 0.09 0.14 0.07 0.18 0.04 
Drug Prescriptions         
Diabetes         
  Any oral hyoglycaemic agent, % 58.7 60.1 69.2 71.5 74.0 76.9 76.7 79.8 
  Metformin, % 54.0 55.3 62.6 65.9 65.7 70.4 67.3 72.5 
  Sulphonylurea, % 13.3 14.1 20.5 23.4 26.0 29.6 29.2 33.5 
  Glitazone, % 2.1 2.2 4.0 4.6 5.0 5.9 5.1 6.6 
  DPP4i, % 1.6 1.7 7.3 7.3 11.3 12.0 14.1 15.7 
  SGLT2i, % 0.1 0.1 0.5 0.5 1.0 1.0 2.1 2.1 
  GLP-1 agonist, % 0.4 0.2 2.2 1.6 3.8 2.9 4.5 3.6 
  Meglitinide, % 0.2 0.2 0.3 0.3 0.3 0.3 0.4 0.3 
  Insulin, % 4.1 3.8 5.4 4.6 7.4 6.3 9.7 9.1 
  Combination, % 0.7 0.9 1.2 1.6 1.3 1.9 1.4 1.8 
         
Antihypertensive agent         
  Any, % 64.5 58.8 68.9 65.7 72.0 69.7 74.2 72.5 
  Alpha-blocker, % 4.8 5.8 6.0 7.3 6.6 8.1 7.3 8.6 
  Angiotensin II receptor blocker, % 13.7 10.2 16.9 13.5 18.9 14.9 19.7 15.9 
  ACE inhibitor, % 34.8 38.2 37.9 44.0 39.5 46.7 41.0 48.3 
  Beta-blocker, % 16.9 13.6 16.5 14.0 17.0 15.0 17.5 15.6 
  Calcium channel blocker, % 25.7 25.9 28.4 29.7 30.3 31.6 31.4 33.4 
  Diuretic: thiazide, potassium     
  sparing or loop, % 
32.8 20.2 31.2 20.2 32.0 21.4 31.9 21.7 
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Risk factor checks, levels, interventions 
and prescriptions 
Year 1 Years 2-3 Years 4-5 Years 6-7 
Women 
N=35,396 
Men 
N=44,589 
Women 
N=24,957 
Men 
N=31,352 
Women 
N=14,996 
Men 
N=18,667 
Women 
N=7,614 
Men 
N=9,257 
n (%) 28,809 
 (81.4) 
33,692 
 (75.6) 
21,018 
 (84.2) 
24,481 
 (78.1) 
12,881 
 (85.9) 
14,944 
 (80.1) 
6,669 
 (87.6) 
7,600  
(82.1) 
Lipid lowering therapy         
  Any, % 62.6 64.1 72.0 72.4 74.0 75.8 75.3 77.6 
  Statin, % 61.5 63.0 70.1 71.0 71.9 74.1 72.9 75.6 
  Fibrate, % 1.0 1.4 1.5 1.8 1.6 2.0 1.7 2.1 
  Ezetimibe, % 3.4 2.7 4.2 3.2 4.7 3.7 5.2 4.0 
  Other, % 2.0 1.8 3.4 2.8 3.4 2.9 3.3 2.5 
         
Antiplatelets         
  Any, % 21.6 23.6 23.5 25.6 22.9 26.2 23.6 28.0 
  Aspirin, % 21.0 23.1 22.7 24.9 22.0 25.3 22.2 26.8 
  Clopidogrel, % 0.9 0.8 1.2 1.2 1.3 1.4 2.0 1.8 
 
Data presented as %,or age-adjusted rate, as indicated 
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Supplemental Table 11. Comparison of the proportions of women and men meeting minimum standards of care over 7 years of follow-up 
years from diagnosis of diabetes  
 
 
Data presented as %; OR, odds ratio (values significantly <1 indicate lower standards of care in women compared to men). Indicators assessed during first 15 months of time block
Minimum Standard of Care Indicator 
Assessed in the Previous 15 Months 
 
Years 2-3 Years 4-5 Years 6-7 
Women 
N=13,917 
Men 
N=17,304 
OR (95% CI) Women 
N=6,839 
Men 
N=8,257 
OR† (95% CI) Women 
N=1,959 
Men 
N=2,252 
OR (95% CI) 
           
1 BMI recorded 91.6 91.8 0.98 (0.90-1.06) 91.6 91.7 0.98 (0.87-1.10) 89.8 91.7 0.80 (0.65-0.99) 
2 HbA1c recorded  94.8 94.7 1.02 (0.92-1.13) 94.8 94.9 0.98 (0.85-1.14) 95.0 95.7 0.84 (0.63-1.12) 
3 Blood pressure recorded  96.5 95.9 1.15 (1.03-1.30) 96.3 95.8 1.15 (0.97-1.35) 95.1 96.0 0.81 (0.60-1.08) 
4 Microalbuminuria tested 45.5 48.8 0.88 (0.84-0.92) 53.3 56.5 0.88 (0.82-0.94) 64.7 69.1 0.82 (0.72-0.93) 
5 Treated with ACE inhibitors if 
proteinuria or microalbuminuria  
51.4 
 
59.0 0.74 (0.64-0.84) 51.3 62.0 0.65 (0.54-0.77) 54.8 62.7 0.72 (0.54-0.96) 
6 Last measured TC ≤5 mmol/l  66.3 76.3 0.61 (0.58-0.64) 67.9 78.4 0.58 (0.54-0.63) 71.8 81.4 0.58 (0.50-0.67) 
 6a      in those with prevalent CVD 72.7 84.4 0.49 (0.42-0.57) 76.5 84.3 0.61 (0.48-0.77) 78.8 86.6 0.57 (0.35-0.93) 
 6b      in those without prevalent CVD 65.5 74.6 0.65 (0.61-0.68) 67.0 77.3 0.60 (0.55-0.64) 71.2 80.6 0.60 (0.61-0.69) 
7 eGFR or serum creatinine testing  95.6 94.8 1.20 (1.08-1.33) 95.2 95.0 1.04 (0.89-1.20) 95.0 95.7 0.85 (0.64-1.14) 
8 Last IFCC-HbA1c ≤59 mmol/mol 
(≤7.5%)  
74.1 71.1 1.16 (1.11-1.22) 69.0 67.0 1.10 (1.02-1.17) 66.3 62.9 1.16 (1.02-1.32) 
9 Last blood pressure ≤140/80mmHg  58.2 56.1 1.09 (1.04-1.14) 61.2 59.2 1.09 (1.02-1.16) 67.3 65.5 1.09 (0.96-1.24) 
 9a      in those with prevalent CVD 62.0 66.6 0.82 (0.72-0.93) 65.4 65.4 1.00 (0.82-1.22) 67.7 66.3 1.06 (0.72-1.58) 
 9b      in those without prevalent CVD 57.7 54.0 1.16 (1.11-1.22) 60.7 58.1 1.12 (1.04-1.20) 67.3 65.3 1.09 (0.95-1.25) 
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Supplemental Table 12. Comparison of the proportion of women and men receiving treatments over 7 years of follow-up years from 
diagnosis of diabetes, stratified by age and cardiovascular disease 
 
 
Data presented as %; OR, odds ratio (values significantly <1 indicate lower standards of care in women compared to men). Indicators assessed during first 15 months of time block 
 
Drug treatment in the Previous 15 
Months 
Years 2-3 Years 4-5 Years 6-7 
Women 
N=13,917 
Men 
N=17,304 
OR (95% CI) Women 
N=6,839 
Men 
N=8,257 
OR (95% CI) Women 
N=1,959 
Men 
N=2,252 
OR (95% CI) 
Treated with ACE inhibitors if 
proteinuria or microalbuminuria 
         
 a <50  46.9 55.7 0.70 (0.48-1.03) 50.7 52.3 0.94 (0.53-1.66) 33.3 59.4 0.34 (0.11-1.08) 
 b ≥50 52.1 59.5 0.74 (0.64-0.86) 51.4 63.0 0.62 (0.52-0.74) 56.4 62.9 0.76 (0.57-1.02) 
Treated with statins 74.3 76.6 0.88 (0.84-0.93) 76.0 79.4 0.82 (0.76-0.89) 78.7 81.7 0.83 (0.71-0.96) 
a <50 with prevalent CVD 75.9 88.8 0.40 (0.14-1.14) 71.4 87.1 0.37 (0.05-2.60) - 100.0 - 
 <50 without prevalent CVD 55.5 64.8 0.68 (0.60-0.76) 58.5 68.6 0.64 (0.53-0.78) 62.1 69.7 0.71 (0.46-1.10) 
b ≥50 with prevalent CVD 84.3 89.7 0.61 (0.51-0.74) 83.6 90.1 0.56 (0.43-0.74) 85.3 90.7 0.59 (0.34-1.04) 
 ≥50 without prevalent CVD 76.3 75.9 1.02 (0.96-1.09) 77.7 79.0 0.93 (0.85-1.02) 79.7 81.3 0.90 (0.76-1.07) 
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Supplemental Table 13. Comparison between men and women with type 2 diabetes for the 
time to intensification of drug regimens after risk factor levels exceed specified thresholds 
along with the probability of treatment intensification stratified by the number of medications 
prescribed for each risk factor and the presence of end organ damage 
 
 
Therapy and Cut-off 
value 
Number of 
drugs at 
baseline 
Months to treatment 
intensification in those with 
treatment modifications 
Probability of treatment 
intensification over 7 years 
from diagnosis 
Women Men P-value Women Men P-value 
Diabetes therapies 
HbA1c >7% (53mmol/mol)       
n=33,050 0 4.3 4.4 0.371 98.2 99.0 0.206 
n=19,965 1 12.1 11.9 0.679 83.7 84.4 0.982 
n=3,271  2+ 12.7 14.5 0.163 59.4 58.8 0.118 
        
HbA1c >8% (64mmol/mol)       
n=18,927 0 2.4 2.6 0.002 99.3 99.4 0.061 
n=14,366 1 10.2 10.3 0.726 88.0 87.1 0.075 
n=3,095  2+ 10.9 12.9 0.055 60.0 63.6 0.085 
        
Antihypertensive therapies 
BP >130/80        
n=22,373 0 5.5 6.4 0.003 82.8 77.6 0.989 
n=10,631 1 7.4 9.2 0.008 75.4 69.3 0.882 
n=11,561  2+ 8.6 9.9 0.186 23.8 30.5 0.139 
        
BP >130/80 and target organ damage       
n=4,376 0 3.1 4.0 0.019 65.4 76.7 0.544 
n=4,846 1 5.4 5.6 0.769 49.6 51.1 0.816 
n=9,199  2+ 5.4 7.9 0.011 21.6 40.9 0.017 
        
BP >140/80        
n=20,652 0 4.4 5.8 <0.001 83.4 81.9 0.021 
n=13,367 1 6.7 8.5 <0.001 75.8 71.4 0.801 
n=17,883  2+ 7.3 9.6 0.001 25.2 33.9 0.068 
        
Lipid-lowering therapies 
LDL >2 or TC>4 and CVD 
      
n=3,797 0 5.0 4.6 0.238 71.5 81.7 <0.001 
n=7,918 1 12.1 10.6 0.415 6.0 6.9 0.819 
n=502  2+ 8.3 8.8 0.908 5.3 6.4 0.689 
        
LDL >2 or TC>4, no CVD       
n=39,086 0 8.5 8.4 0.509 80.3 82.9 0.976 
n=18,464 1 20.4 17.2 0.066 5.9 5.9 0.419 
n=507  2+ 12.1 11.5 0.908 7.2 4.7 0.394 
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Supplemental Table 14. Comparison of unadjusted hazard ratios for MACE events in incident T2DM and prevalent T2DM patients  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Incident T2DM N=79,985; Controls N=386,547 
† Prevalent T2DM N=77,494; Controls N=294,213 
Model 
Diabetes 
cohort 
 Primary Outcome: MACE Secondary Outcome: MI  
(fatal/non-fatal) 
Secondary Outcome: Stroke (fatal/non-
fatal) 
Risk of CV 
associated with the 
presence of diabetes;  
HR (95% CI) 
Ratio of risks 
between women 
and men; 
RRR (95% CI) 
Risk of CV  
associated with the 
presence of diabetes;  
HR (95% CI) 
Ratio of risks 
between women 
and men; 
RRR (95% CI) 
Risk of CV  
associated with the 
presence of diabetes; 
 HR (95% CI) 
Ratio of risks 
between women 
and men; 
RRR (95% CI) 
1 Incident 
T2DM * 
 
Women 1.44 (1.36-1.52) 
1.05 (0.98-1.13) 
1.68 (1.56-1.81) 
1.09 (0.99-1.20) 
1.24 (1.13-1.37) 
1.06 (0.92-1.22) 
Men 1.37 (1.31-1.44) 1.54 (1.45-1.64) 1.17 (1.06-1.30) 
1 Prevalent 
T2DM † 
 
Women 1.53 (1.24-1.82) 
1.06 (0.82-1.37) 
1.75 (1.27-2.04) 
1.09 (0.80-1.47) 
1.43 (1.06-2.10) 
1.12 (0.71-1.77) 
Men 1.45 (1.22-1.72) 1.61 (1.34-2.07) 1.28 (0.95-1.75) 
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